Looking at the filing, this is an S-1/A (Amendment No. 3) registration statement for NuvOx Therapeutics, Inc. The cover page indicates they intend to apply to list on NYSE American under the symbol "NUOX." The reference ticker context mentions NASDAQ:NUOX, but the filing itself states NYSE American under "NUOX" - I must use what the filing states. The substantive disclosure content includes the offering details: 2,860,000 shares of common stock, anticipated IPO price between $6.00 and $8.00, over-allotment option for up to 429,000 additional shares, underwriter ThinkEquity, and listing application for NYSE American under "NUOX." This is well over 150 words of substantive content. The filing does not show a ticker already trading - this is an IPO registration. The filing states the intended exchange as "NYSE American" and symbol "NUOX."

NuvOx Therapeutics, Inc. filed Amendment No. 3 to its Form S-1 registration statement with the U.S. Securities and Exchange Commission on October 28, 2026, covering a proposed initial public offering of 2,860,000 shares of common stock with an anticipated price range of $6.00 to $8.00 per share.

Key Highlights

  • Shares offered: 2,860,000 shares of common stock in an initial public offering, with no prior public market for the shares.
  • Price range: The company anticipates an initial public offering price between $6.00 and $8.00 per share, according to the filing.
  • Over-allotment option: The underwriters have been granted a 45-day option to purchase up to 429,000 additional shares solely to cover over-allotments.
  • Proposed listing: The company intends to apply to list its common stock on the NYSE American under the symbol "NUOX," subject to final approval.
  • Underwriter: ThinkEquity is named as the underwriter for the offering.
  • Company classification: NuvOx Therapeutics is identified in the filing as an "emerging growth company" and a "smaller reporting company" under federal securities laws.

NuvOx Therapeutics Details Terms of Proposed Initial Public Offering

NuvOx Therapeutics, Inc., a Delaware-incorporated company with principal executive offices at 1635 E. 18th Street, Tucson, AZ 85719, submitted Amendment No. 3 to its Form S-1 registration statement under Registration No. 333-297520. According to the filing, this is the company's initial public offering, and "prior to this offering, there has been no public market for our common stock." The prospectus is described as preliminary and subject to completion.

The filing discloses that 2,860,000 shares of common stock are being offered, with an anticipated price range of $6.00 to $8.00 per share. The representative of the underwriters holds a 45-day option to purchase up to an additional 429,000 shares solely to cover over-allotments. Per-share and total figures for the initial public offering price, underwriting discount, and proceeds to NuvOx before expenses are listed as blank in the preliminary prospectus, as the final pricing had not been set at the time of filing. The company disclosed that it has agreed to pay the underwriters for certain expenses and directed readers to the "Underwriting" section beginning on page 166 of the prospectus for additional compensation details.

The company stated it intends to apply to list its common stock on the NYSE American under the symbol "NUOX," noting that "this offering is contingent upon final approval by the NYSE American of our listing." Rong Wang is identified as President and Chief Executive Officer. Blank Rome LLP and Venable LLP are listed as legal counsel. The filing also notes that NuvOx has elected to comply with "certain reduced public company reporting requirements" available to emerging growth companies and smaller reporting companies. The prospectus contains forward-looking statements that the company identifies as its own and subject to its cautionary language beginning on page 64.

What Was Disclosed

NuvOx Therapeutics filed a third amendment to its S-1 registration statement on October 28, 2026, disclosing plans for an IPO of 2,860,000 common shares at an anticipated range of $6.00 to $8.00, with ThinkEquity as underwriter and a proposed NYSE American listing under "NUOX."